Dendritic cell receptor

Details Dendritic cell receptor Dendritic cell receptor

1999-03-18

2002-08-13

Eyler, Yvonne (Department: 1647)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S070100, C435S071100, C435S471000, C435S325000, C435S252300, C435S320100, C536S023100, C536S023500, C530S350000

Reexamination Certificate

active

06432666

ABSTRACT:

CROSS REFERENCE TO RELATED APPLICATIONS
This application is a 371 of WO 97/45449.
FIELD OF THE INVENTION
This invention relates to dendritic cell receptors. In particular, it relates to human DEC-205, to the production and use thereof, and to ligands which bind to it. Human DEC-205 and its ligands are useful in prophylaxis and therapy.
BACKGROUND OF THE INVENTION
Dendritic cells perform important immunoregulatory functions by presenting antigens in the form of peptides bound to cell-surface major histocompatibility complex (MHC) molecules to T cells. Identification of the mechanism by which this antigen presentation function is achieved therefore has important implications in manipulating immune response in prophylaxis and therapy, particularly in humans.
Jiang et al,
Nature
375: 151-155 (1995) disclose a murine dendritic cell receptor having a molecular weight of 205 kDa (murine DEC-205). However, they do not disclose a receptor on human dendritic cells.
The applicant has now identified a receptor on human dendritic cells. It is broadly to this receptor (likely to be the human homolog of murine DEC-205) that the present invention is directed.
SUMMARY OF THE INVENTION
The present invention has a number of aspects. In a first aspect, the invention provides isolated human DEC-205 which has an approximate molecular weight of 198-205 kDa and which includes the following amino acid sequences:
(i) TVDCNDNQPGAICYYSGNETEKEVKPVDSVKCPSPVLNTPWIPF QNCCYNFIITKNRHMATTQDEVQSTCEKLHPKSHILSIRDEKE NNFVLEQLLYFNYMASWVMLGITYRNNSL (amino acids at positions 1208-1323 of SEQ ID NO:1) and
(ii) SQHRLFHLHSQKCLGLDITKSVNELRMFSCDSSAML (amino acids at positions 71-106 of SEQ ID NO:1)
or a functionally equivalent fragment thereof.
In a further aspect, the invention provides isolated human DEC-205 which comprises the amino acid sequence shown in
FIG. 11
or a functionally equivalent fragment thereof
In a still further aspect, the invention provides isolated mature human DEC-205, which comprises the amino acids 27 to 1722 shown for human DEC-205 in FIG.
11
.
In yet a further aspect, the invention provides an extracellular domain of human DEC-205 or a functionally-equivalent fragment thereof.
In a preferred embodiment, the extracellular domain fragment includes at least a portion of carbohydrate recognition domain (CRD7), spacer, and a portion of carbohydrate recognition domain (CRD8) of human DEC-205 (amino acids 1208 to 1323 of the amino acid sequence of FIG.
11
).
In a still further aspect, the invention provides a polynucleotide encoding human DEC-205 or its extracellular domain as defined above. This polynucleotide is preferably DNA, more preferably cDNA, but can also be RNA.
In a specific embodiment, the polynucleotide coding for human DEC-205 includes the following nucleotide sequences (SEQ ID NOS:3& 4, respectively, in order of appearance):
(iii)  A ACA GTT GAT TGC AAT GAC AAT CAA CCA GGT GCT ATT TGC

     TAC TAT TCA GGA AAT GAG ACT GAA AAA GAG GTC AAA CCA GTT

     GAC AGT GTT AAA TGT CCA TCT CCT GTT CTA AAT ACT CCG TGG

     ATA CCA TTT CAG AAC TGT TGC TAC AAT TTC ATA ATA ACA AAG

     AAT AGG CAT ATG GCA ACA ACA CAG GAT GAA GTT CAT ACT AAA

     TGC CAG AAA CTG AAT CCA AAA TCA CAT ATT CTG AGT ATT CGA

     GAT GAA AAG GAG AAT AAC TTT GTT CTT GAG CAA CTG CTG TAC

     TTC AAT TAT ATG GCT TCA TGG GTC ATG TTA GGA ATA ACT TAT

     AGA AAT AAX TCT CTT;and

 (iv)  ATT AAT ATG CTG TGG AAG TGG GTG TCC CAG CAT CGG CTC TTT

       CAT TTG CAC TCC CAA AAG TGC CTT GGC CTC GAT ATT ACC AAA

       TCG GTA AAT GAG CTG AGA ATG TTC AGC TGT GAC TCC AGT GCC

       ATG CTG TGG TGG AAA TGC GAG CAC CA
where X is T or G.
In a further embodiment, the polynucleotide comprises part or all of the nucleotide sequence of FIG.
10
.
In yet a further aspect, the invention provides a vector including a polynucleotide as defined above.
In still a flrter aspect, the invention provides a method of producing human DEC-205, the extracellular domain thereof or a fimctional fragment comprising the steps of:
(a) culturing a host cell which has been transformed or transfected with a vector as defined above to express the encoded human DEC-205, extracelhular domain or fragment; and
(b) recovering the expressed human DEC-205, extracellular domain or fragment.
As yet an additional aspect, the invention provides a ligand that binds to human DEC-205 or its extracellular domain as defined above.
Preferably, the ligand is an antibody or antibody binding fragment or carbohydrate bearing protein.
The antibody or antibody binding fragment can be used in methods for extracting or isolating activated dendritic cells.
In still a further aspect, the invention provides a construct for use in therapy or prophylaxis. The construct will usually be a ligand-antigen construct or a DEC-205-antigen construct although ligand-toxin and DEC-205-toxin constructs are also contemplated. The ligand-antigen construct preferably consists of an antibody or antibody binding fragment which binds to human DEC-205 and a host-protective antigen. The DEC-205-antigen construct preferably consists of at least the extra-cellular domain of human DEC-205 and a host-protective antigen.
In yet further aspects, the invention contemplates methods of therapy or prophylaxis which employ human DEC-205, ligands or constructs containing them.
In yet a further aspect, the invention provides a molecule (hapten) which may be used to generate antibodies for identifying or puring human dendritic cells, which includes a peptide based upon part or all of the sequence of FIG.
11
.


REFERENCES:
patent: 96/23882 (1996-08-01), None
Cellular Immunology (1195) vol. 165, pp. 302-311 by Swiggard WJ et al. “DEC-205, a 205-kDa protein abundant on mouse dendritic cells and thymic epithelium that is detected by the monoclonal antibody NLDC-145; Purification, characterisation and N-terminal amino acid sequence” See the entire document.
Swiggard et al, “DEC-205, a 205-kDa Protein Abundant . . .,” Cellular Immunology, vol. 165, pp. 302-311 (1995).

Affiliated with

Also associated with

Rating

Dendritic cell receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dendritic cell receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dendritic cell receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2877951